Brief: Alkermes Announces Initiation Of Vibrance-3 Phase 2 Study Evaluating Alks 2680 For The Treatment Of Idiopathic Hypersomnia
01/04/2025 12:09
April 1 (Reuters) - Alkermes Plc ALKS.O: ALKERMES ANNOUNCES INITIATION OF VIBRANCE-3 PHASE 2 STUDY EVALUATING ALKS 2680 FOR THE TREATMENT OF IDIOPATHIC HYPERSOMNIA Source text: ID:nPn4VhWZLa Further company coverage: ALKS.O ((Reuters.Briefs@thomsonreuters.com;))